Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 926

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Open access
Tilly, Hervé, Morschhauser, Franck, Sehn, Laurie H., Friedberg, Jonathan W., Trněný, Marek, Sharman, Jeff P., Herbaux, Charles, Burke, John M., Matasar, Matthew, Rai, Shinya, Izutsu, Koji, Mehta-Shah, Neha, Oberic, Lucie, Chauchet, Adrien, Jurczak, Wojciech, Song, Yuqin, Greil, Richard, Mykhalska, Larysa, Bergua-Burgués, Juan M., Cheung, Matthew C., Pinto, Antonio, Shin, Ho-Jin, Hapgood, Greg, Munhoz, Eduardo, Abrisqueta, Pau, Gau, Jyh-Pyng, Hirata, Jamie, Jiang, Yanwen, Yan, Mark, Lee, Calvin, Flowers, Christopher R., Salles, Gilles·2022·New England Journal of Medicine

Abstract

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells. METHODS: We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18 to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival and safety. RESULTS: Overall, 879 patients underwent randomization: 440 were assigned to the pola-R-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2 months, the percentage of patients surviving without progression was significantly higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI, 0.57 to 0.95; P = 0.02). Overall survival at 2 years did not differ significantly between the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6% [95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI, 0.65 to 1.37; P = 0.75). The safety profile was similar in the two groups. CONCLUSIONS: Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2115304

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 926

Metadata

Authors
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y., Greil, R., Mykhalska, L., Bergua-Burgués, J. M., Cheung, M. C., Pinto, A., Shin, H.-J., Hapgood, G., Munhoz, E., Abrisqueta, P., Gau, J.-P., Hirata, J., Jiang, Y., Yan, M., Lee, C., Flowers, C. R., & Salles, G.
Venue
New England Journal of Medicine
Published
2022-01-27
Volume
386
Issue
4
Pages
351-363
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4200197309
Cited by
926
References
35
FWCI
63.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1056/nejmoa2115304
The paper
Tilly, H., Morschhauser, F., Sehn, L. H., Friedberg, J. W., Trněný, M., Sharman, J. P., Herbaux, C., Burke, J. M., Matasar, M., Rai, S., Izutsu, K., Mehta-Shah, N., Oberic, L., Chauchet, A., Jurczak, W., Song, Y., Greil, R., Mykhalska, L., Bergua-Burgués, J. M., . . . Salles, G. (2022). Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2115304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.